Credits Available: 4.25 AMA PRA Category 1 Credits™, 4.25 ANCC Contact Hours, 4.25 ACPE

Description: This dynamic curriculum, detailed by a specialty center clinician, explores each of the CD 19-directed CAR T-cell therapies available for the treatment of DLBCL; solutions to referral and logistic challenges; in-depth early and late toxicity management in CAR T-cell treatment; and the delivery of goal-concordant care using shared decision-making strategies. A challenging real-world case scenario discussion within each Gather-ed group highlights critical decision points, key challenges, and opportunities to incorporate collective insights.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Pharmacist, Physician Assistant, Nurse, Pharmacy Director
Target Specialties: Hematology, Hematology/Oncology, Oncology

Anna Rivard

Billings Clinic Cancer Center
Lead Oncology Clinical Pharmacy Specialist

I believe all patients deserve high-quality care, regardless of location. I am passionate about bringing the most up-to-date, evidence-based cancer treatments to patients, even in rural areas. I have spearheaded the implementation of a CAR-T trial in 2019 including multi-disciplinary team coordination and education. I also spearheaded the implementation of bispecific t-cell engager use at our facility (multiple agents for multiple disease states). I have presented on the latter at local, regional, and national levels. Our site currently refers out for CAR-T but we are reviewing our ability to start CAR-T therapy at our facility very soon.

Outside of work, I enjoy spending time outdoors-- hiking, rock climbing, or simply relaxing outside with my family.